From bringing in a mere 350 scientists in an embattled field 12 years ago, this year's Alliance for Regenerative Medicine Cell and Gene Meeting brought in more than 1,200.
Edited to include comments from CEO. Halfway through its first large-scale efficacy trial, Athersys’s experimental stem cell therapy did not provide significant benefit to patients with moderate-to-severe ulcerative colitis. But the company isn’t too worried about what that might mean just yet. Cleveland-based Athersys (NASDAQ: ATHX) released the interim results today for the Phase 2 […]
Athersys (NYSE:ATHX) is looking to Japan for potential opportunities to bring its MultiStem therapies to market quicker. In its annual financial results call on Thursday, Athersys’ chief operating officer, BJ Lehmann, explained that legislation passed last fall in Japan could allow for conditional approval of new regenerative medicines that demonstrate strong safety profiles in clinical […]
Thanks in part to a SBIR Fast Track grant worth up to $2.8 million, stem cell company Athersys (Nasdaq: ATHX) is gearing up to advance its third MultiStem program into Phase 2 clinical trials. Cleveland-based Athersys develops an off-the-shelf biologic product made from adult stem cells that it’s applying to disease indications in inflammation, neurology […]
Cleveland-based Athersys (NYSE:ATHX) has a full plate as it continues to advance its “off the shelf” stem cell therapy, MultiStem, through clinical trials in several indications. That means shareholders can expect more R&D spending and potential new partnerships this year as the company continues developing MultiStem and its 5HT2C agonist program. Athersys CEO Gil Van […]
It isn’t easy to get profit-hungry Wall Street excited about a drug that hasn’t yet been tested in humans and is at best years and years away from generating any sales, but Athersys (NASDAQ:ATHX) CEO Gil Van Bokkelen did his best in a recent conference call with investment analysts. That’s because there are recent signs […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Stem cell therapeutics developer Athersys’ (NASDAQ:ATHX) phase 2 clinical study investigating the treatment of inflammatory bowel disease with partner Pfizer (NYSE:PFE) is expected to complete patient enrollment by the end of 2012. Top-line results of the inflammatory bowel disease trial are likely to be available in early 2013, Athersys CEO Gil Van Bokkelen said in […]
Results of a preclinical study suggest that stem cell technology from Athersys (NASDAQ:ATHX) could offer a treatment for patients suffering from a rare disorder called “Hurler’s syndrome.” Hurler’s syndrome is a metabolic disorder in which patients produce too little of an enzyme that helps the body break down a complex type of sugar molecule found […]
Stem cell developer Athersys (NASDAQ:ATHX) has received a U.S patent that covers the use of nonembryonic, multipotent stem cells in the treatment of graft-versus-host disease. Graft-versus-host disease (GvHD) often occurs after a stem cell or bone marrow transplant in which the newly transplanted material attacks the transplant recipient’s body. The condition is often associated with […]
Gil Van Bokkelen, CEO of stem cell company Athersys (NASDAQ:ATHX), is typically one to speak in cautious and measured tones, but he made a brash statement in the company’s most recent quarterly earnings call. Van Bokkelen said Cleveland-based Athersys’ MultiStem stem cell therapy for ischemic stroke “could easily be one of the biggest blockbusters that […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Stem cell developer Athersys (NASDAQ:ATHX) has received German regulatory clearance for a physician-sponsored solid organ transplant clinical trial. The study will enroll up to 24 patients and examine Athersys’ MultiStem technology in reducing the likelihood of rejection in patients who’ve undergone liver transplants, CEO Gil Van Bokkelen said in a call to discuss the company’s […]
Stem cell developer Athersys (NASDAQ:ATHX) has secured $9 million in a private placement with an unidentified investor. Cleveland-based Athersys said it would issue about 4.3 million shares of common stock and an equal number of warrants to purchase common shares at a price of $2.07. The warrants are exercisable for five years, according to a […]
University Hospitals Case Medical Center will be one of 25 institutions in the U.S. to take part in a phase 2 clinical trial of a stem cell treatment for stroke developed by Cleveland-based Athersys (NASDAQ:ATHX). The Plain Dealer reports that MultiStem will be administered via a one-time IV infusion to 140 patients at UH and […]
Stem cell therapy developer Athersys (NASDAQ:ATHX) reported positive results from a phase 1 clinical trial in patients with leukemia and similar blood diseases. The trial showed that the company’s MultiStem technology may reduce the incidence and severity of graft-versus-host disease, according to a statement from Cleveland-based Athersys. Graft-versus-host disease (GvHD) often occurs after a stem […]
Stem cell developer Athersys (NASDAQ:ATHX) has received $3.6 million in new grant funding, with one of the grants going toward studying its MultiStem technology for the treatment of traumatic brain injury. A $1.9 million grant to study traumatic brain injury (TBI) comes from the National Institute of Neurological Disorders and Stroke, according to a statement […]
